Actively Recruiting
Study of Lunsekimig Compared to Placebo in Adults With COPD Characterized by an Eosinophilic Phenotype
Led by Sanofi · Updated on 2026-10-19
942
Participants Needed
314
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
CONDITIONS
Brief Title
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here